New hope for rare cancers: drug combo trial launches
NCT ID NCT06161532
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times
Summary
This phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study aims to see how many participants respond to treatment and how long the effects last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan and atezolizumab
- What this could lead to
- If successful, this could provide a new treatment option for people with rare genitourinary cancers that are hard to study and have few approved therapies.
- What could go wrong
- This is a small, early-phase trial (60 participants) with no control group, so results may not apply broadly. Both drugs have known side effects, including immune-related reactions and low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY ADENOCARCINOMA OF THE BLADDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New drug cocktail targets rare, aggressive kidney cancer
- Immunotherapy combo tested for rare kidney cancer, but trial stopped early
- Scientists launch Largest-Ever study of rare bladder and genital cancers
- New combo therapy targets rare, aggressive kidney tumors
- New hope for rare cancers: drug combo shows promise in early trial